Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | — | — | — | — | -$14.1M | -$8.09M |
| Net income | -$4.60M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$7.97M |
| EPS (diluted) | -$0.74 | -$1.49 | -$1.12 | -$1.15 | -$17.45 | -$5.32 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.35M | -$5.01M | -$7.54M | -$9.80M | -$10.4M | -$6.79M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.18M | $13.0M | $9.11M | $7.47M | $3.71M | $7.56M |
| Total assets | $3.22M | $13.3M | $9.38M | $7.71M | $3.86M | $7.69M |
| Total liabilities | $522K | $844K | $2.06M | $3.04M | $3.24M | $2.42M |
| Shareholders' equity | $2.70M | $12.4M | $7.32M | $4.67M | $615K | $5.27M |
| Retained earnings | -$13.8M | -$26.5M | -$38.6M | -$53.2M | -$67.3M | -$75.3M |
| Shares (wtd avg diluted) | 6.19M | 8.54M | 10.8M | 12.7M | 808K | 1.50M |
Every figure is extracted from Acurx Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.